^
    Back
    Association details:
    Biomarker:MYD88 mutation
    Cancer:Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) +
    Calquence (acalabrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ICML 2023
    Title:

    Combination of acalabrutinib with rituximab and lenalidomide in relapsed/refractory B cell non-Hodgkin lymphoma

    Published date:
    06/09/2023
    Excerpt:
    A total of 7 patients were found to have MYD88 mutation. Among these patients, total of six patients with MYD88 mutation showed objective response to the R2A regimen with three CR patients….R2A regimen showed meaningful efficacy and durable clinical response in patients with relapsed/refractory B cell NHL with tolerable toxicity profiles.
    DOI:
    https://doi.org/10.1002/hon.3164_326
    Trial ID:
    NCT04094142